Karyopharm Therapeutics
Pharmaceuticals, 85 Wells Ave Fl 2, Newton, Massachusetts, 02459, United States, 201-500 Employees
Phone Number: 88********
Who is KARYOPHARM THERAPEUTICS
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs dir...
Read More
-
Headquarters: 85 Wells Ave Fl 2, Newton, Massachusetts, 02459, United States
-
Date Founded: 2008
-
Employees: 201-500
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from KARYOPHARM THERAPEUTICS
Karyopharm Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Karyopharm Therapeutics
Answer: Karyopharm Therapeutics's headquarters are located at 85 Wells Ave Fl 2, Newton, Massachusetts, 02459, United States
Answer: Karyopharm Therapeutics's phone number is 88********
Answer: Karyopharm Therapeutics's official website is https://karyopharm.com
Answer: Karyopharm Therapeutics's revenue is $100 Million to $250 Million
Answer: Karyopharm Therapeutics's SIC: 2834
Answer: Karyopharm Therapeutics's NAICS: 325412
Answer: Karyopharm Therapeutics has 201-500 employees
Answer: Karyopharm Therapeutics is in Pharmaceuticals
Answer: Karyopharm Therapeutics contact info: Phone number: 88******** Website: https://karyopharm.com
Answer: Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharms lead compound, XPOVIO (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month